Pediatrix Medical Group Reports Strong Q1 2026 Performance
Pediatrix Medical Group reported robust first-quarter performance in 2026, driven by a 4% pricing growth that offset modest volume declines. The company reaffirmed its full-year adjusted EBITDA guidance of $280 million to $300 million and emphasized strategic initiatives including clinical quality improvements and teleservices expansion.
Tickers: $MD
Topics: clinical strategy ebitda guidance financial performance pricing growth